In adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea-hypopnea events vs. placebo.
Where this comes from
- Record sourced from PubMed, PMID 39348697.
- Also identified by DOI 10.7326/ANNALS-24-02174-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. <b>Tirzepatide for the treatment of obstructive sleep apnea and obesity.</b> N Engl J Med. 21 Jun 2024. [Epub ahead of print.] 38912654.